Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: IN_GOD_I_TRUST who wrote (2156)	7/24/1998 11:58:00 AM
From: jopawa	Read Replies (1) \| Respond to of 4676

Steve, We had our chance yesterday to breakout above 16. There is a heavy lid on this stock at 16, and it is going to be very hard to lift. There were 2 huge volume days, yesterday and a day back in Feb., that sucked in traders between 15-16. It is a shame that we didn't get the hype yesterday to follow up on Wed afternoon. That's the breaks though. John

To: IN_GOD_I_TRUST who wrote (2156)	7/24/1998 12:23:00 PM
From: tom jones	Respond to of 4676

To all: ISIP price? Most funds can not buy a stock until they do research and then the managers must discuss it. So it will take time before the institutions start buying. Even if we knew that antisense works it is still going to take a very long time to get other drugs to market and Drug delivery is still a big problem. There has been about 2 million shares short for a very long time which may mean that they are held buy one person or group. If this person or group is close to the market makers they may be getting some help to cover their shorts at a low price. These shorts did not cover when the stock price went to $20, 19 and 18 at different times which may mean they knew they could get help to buy back at lower prices. Short interest will be out soon. Mike Murphy was just on KWHY-TV and he did not talk about Isis. Tom

To: IN_GOD_I_TRUST who wrote (2156)	7/24/1998 1:17:00 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 4676

Failed short term pop expectations? TTNP is also down materialy this week after a good announcement. Makes no sense - will be interesting to some TA tonight. Well probably have a Bolinger band violation, but RSI & STOC wil probably be way to high to call it oversold, so further errorion is possible even if it makes no sense. Scott

To: IN_GOD_I_TRUST who wrote (2156)	7/24/1998 3:15:00 PM
From: tommysdad	Read Replies (1) \| Respond to of 4676

Approval? Again, an FDA advisory panel rec is NOT final approval. It was not a unanimous vote. The panel actually wanted ISIS to test more patients to get better statistics -- BUT -- there aren't enough patients out there to accrue subjects for the trials. What does that tell you about the potential market for this product? It's injected directly into the eye, so forget off-label usage. And, to top it off, BioWorld Today quoted an FDA official as saying he didn't think fomavirsen demonstrated enough efficacy to qualify as first-line therapy. That is a hint that FDA may not approve the drug as first-line therapy (they may, but it's not a slam dunk). Second-line therapy for a shrinking indication = how many $$$??? Don't get me wrong, this is a great plus scientifically for ISIS. Congratulations to them. But, realistically, how much money can you expect them to make off this drug? Maybe that's what the Street is thinking.